First, the FDAs resolution of the semaglutide and tirzepatide shortages in mid-2024 ended the broad compounding allowance under section 503A, narrowing the legal path for compounded versions to patients with documented medical need (specific dose unavailable, sensitivity to a commercial inactive ingredient)
Upper Arms The back of the upper arm can be used, though some patients find it less convenient to reach

Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
The beta amyloid dysfunction (BAD) hypothesis for Alzheimers disease
Oral GLP-1 Option The website advertises an oral GLP-1 plan but does not publicly identify its exact active medicine, formulation, strength or dosing schedule
Products formulated for better absorption may be more effective